Search results for "Genetically engineered"

showing 4 items of 14 documents

Responsibility and intellectual property in synthetic biology: A proposal for using Responsible Research and Innovation as a basic framework for inte…

2015

Synthetic biology (SynBio) is an engineering view of biotechnology that has the potential to increase the number and industrial utility of biotechnological applications by implementing engineering principles such as standardization and modularity. The boundaries between SynBio, biotechnology, and metabolic engineering are not always clear, but assessing SynBio in a wider sense—that of modeling‐based biotechnology and/or “sophisticated” metabolic engineering—we find that a significant number of applications and research articles have been generated in the past few years [1]. One of the best‐known examples is that of a synthetic pathway for producing artemisinic acid, a precursor to the antim…

Responsible Research and InnovationStandardizationInternational Genetically Engineered Machinebusiness.industryResearchIntellectual propertyBiologyBiochemistryModularityIntellectual PropertyBiotechnologySynthetic biologyGeneticsHumansPatentabilityEngineering ethicsRelevance (information retrieval)Synthetic BiologybusinessMolecular BiologyScience & Society
researchProduct

A microplate version of the SOS/umu-test for rapid detection of genotoxins and genotoxic potentials of environmental samples

1991

Abstract The umu-microtest is a miniaturized automated short-term test version proposed for screening of umuC-dependent mutagenic potentials of chemicals relevant to environmental pollution, river water and industrial waste water. The test is based on the SOS/umu-test and has been modified in order to allow extensive testing of environmental samples. Genetically engineered Salmonella typhimurium (TA1535/pSK1002) are incubated on a microplate rotor in a sloping position for 2 h with the test samples, followed by addition of fresh culture medium to reach a 10-fold dilution of the incubation medium. 2 h later, the activity of the β-galactosidase, which reflects umuC induction, is determined co…

Salmonella typhimuriumAzidesEnvironmental pollutionToxicologyRiver waterRapid detectionMicrobiologyIndustrial waste waterGeneticsSOS responseSOS Response GeneticsSodium AzideIncubationChromatographyMutagenicity TestsChemistryGenetically engineeredGene Expression Regulation BacterialHydrogen-Ion Concentrationbeta-GalactosidaseDilutionMutagenesisMicrosomes LiverWater Pollutants ChemicalEnvironmental MonitoringMutagensMutation Research/Environmental Mutagenesis and Related Subjects
researchProduct

Genetically engineered V79 Chinese hamster cells metabolically activate the cytostatic drugs cyclophosphamide and ifosfamide.

1990

V79 cells, genetically engineered to express active cytochromes P450IIB1 and P450IA1, were used to study the cytotoxicity and mutagenicity of cyclophosphamide and ifosfamide. Cyclophosphamide, tested up to a concentration of 2 mM, was not cytotoxic in V79 nor in the P450IA1-expressing V79-derived cell line XEM2. Pronounced cytotoxicity was, however, observed in the P450IIB1-expressing V79-derived cell line SD1. Induction of gene mutations (acquisition of 6-thioguanine resistance) was observed in SD1 cells as well, but the effects were weak. Ifosfamide was inactive in V79 cells, but was cytotoxic in SD1 cells. Ifosfamide mustard, an active metabolite of ifosfamide, was equally cytotoxic and …

endocrine systemCyclophosphamideHealth Toxicology and MutagenesisAntineoplastic AgentsPharmacologyChinese hamsterCell LineBiotransformationCricetinaemedicineAnimalsIfosfamideCytotoxicityCyclophosphamideBiotransformationIfosfamidebiologyGenetically engineeredPublic Health Environmental and Occupational Healthfood and beveragesrespiratory systembiology.organism_classificationCell cultureCytostatic drugsGenetic EngineeringResearch Articlemedicine.drugEnvironmental Health Perspectives
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct